JOHNSON & JOHNSON
10-Q, EX-27, 2000-10-31
PHARMACEUTICAL PREPARATIONS
Previous: JOHNSON & JOHNSON, 10-Q, 2000-10-31
Next: HARRIS CORP /DE/, S-8, 2000-10-31



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                                OCT-1-2000
<CASH>                                            3550
<SECURITIES>                                      2037
<RECEIVABLES>                                     4613
<ALLOWANCES>                                       401
<INVENTORY>                                       3022
<CURRENT-ASSETS>                                 15225
<PP&E>                                           11207
<DEPRECIATION>                                    4588
<TOTAL-ASSETS>                                   30784
<CURRENT-LIABILITIES>                             6665
<BONDS>                                           2437
                                0
                                          0
<COMMON>                                          1535
<OTHER-SE>                                       16951
<TOTAL-LIABILITY-AND-EQUITY>                     30784
<SALES>                                          22031
<TOTAL-REVENUES>                                 22031
<CGS>                                             6676
<TOTAL-COSTS>                                     6676
<OTHER-EXPENSES>                                  1996
<LOSS-PROVISION>                                    28
<INTEREST-EXPENSE>                                 115
<INCOME-PRETAX>                                   5504
<INCOME-TAX>                                      1595
<INCOME-CONTINUING>                               3909
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      3909
<EPS-BASIC>                                     2.81
<EPS-DILUTED>                                     2.77


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission